Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival

Little is known about the molecular factors that are altered in remitting bipolar disorder (BD) patients. We carried out proteome profiling of peripheral blood mononuclear cells (PBMCs) and serum from BD patients who were not experiencing mania or major depression (euthymia) compared to matched healthy controls using liquid chromatography–mass spectrometry (LC‐MSE) and Multi‐Analyte Profiling (Human Map®) platforms. This resulted in the identification of approximately 60 differentially expressed molecules involved predominantly in cell death/survival pathways. In PBMCs, this was manifested in cytoskeletal and stress response‐associated proteins, whereas most serum analytes were associated with the inflammatory response. The predicted effect of serum analytes on physiological systems was tested by treating PBMCs with serum obtained from the same patients, resulting in reduced cellular survival. These preliminary results suggest that BD patients carry a peripheral fingerprint that has detrimental effects on cell function and that could be used to distinguish BD patients from healthy controls despite being in a remission phase. It is hoped that additional studies of BD patients in the manic and depressed stages could lead to the identification of a molecular fingerprint that could be used for predicting episodic switching and for guiding treatment strategies.

[1]  Lan Wang,et al.  Global proteomic profiling reveals altered proteomic signature in schizophrenia serum , 2010, Molecular Psychiatry.

[2]  M. Webster,et al.  Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders , 2010, Molecular Psychiatry.

[3]  G. Cagney,et al.  Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression , 2009, Molecular Psychiatry.

[4]  J. Aubry,et al.  Early effects of mood stabilizers on the Akt/GSK-3β signaling pathway and on cell survival and proliferation , 2009, Psychopharmacology.

[5]  S. Baron-Cohen,et al.  Real-time evaluation of experimental variation in large-scale LC-MS/MS-based quantitative proteomics of complex samples. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  H. Stolp,et al.  Review: Role of developmental inflammation and blood–brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases , 2009, Neuropathology and applied neurobiology.

[7]  H. Kenna,et al.  Reproductive and Metabolic Abnormalities Associated with Bipolar Disorder and Its Treatment , 2009, Harvard review of psychiatry.

[8]  I. Huhtaniemi,et al.  Sex in the brain: How the brain regulates reproductive function , 2009 .

[9]  Philip D. Harvey,et al.  Neurocognitive impairment in bipolar disorder patients: functional implications. , 2009, Bipolar disorders.

[10]  Dan Golick,et al.  Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures , 2009, Proteomics.

[11]  F. Mármol Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  Wesley S Wiggins,et al.  Multianalyte Profiling of Serum Antigens and Autoimmune and Infectious Disease Molecules to Identify Biomarkers Dysregulated in Epithelial Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[13]  P. McKenna,et al.  High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. , 2008, Journal of proteome research.

[14]  W. Nolen,et al.  A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. , 2008, Archives of general psychiatry.

[15]  E. Emanuele,et al.  Increased proapoptotic serum activity in patients with chronic mood disorders. , 2008, Archives of medical research.

[16]  Ying Zhang,et al.  Comparative Proteomics and Correlated Signaling Network of Rat Hippocampus in the Pilocarpine Model of Temporal Lobe Epilepsy , 2007 .

[17]  Sun-Hwa Park,et al.  Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. , 2007, Journal of affective disorders.

[18]  S. Kennedy,et al.  Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? , 2007, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[19]  M. Berk,et al.  Early intervention in bipolar disorders: opportunities and pitfalls , 2007 .

[20]  R. Faull,et al.  Differences in Protein Profiles in Schizophrenia Prefrontal Cortex Compared to Other Major Brain Disorders , 2007 .

[21]  Emanuel Schwarz,et al.  Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. , 2007, Journal of separation science.

[22]  M. E. Hernández,et al.  Immune variations in bipolar disorder: phasic differences. , 2007, Bipolar disorders.

[23]  Jack van Honk,et al.  Testosterone administration reduces empathetic behavior: A facial mimicry study , 2006, Psychoneuroendocrinology.

[24]  I. Ferrier,et al.  Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. , 2006, Bipolar disorders.

[25]  J. Rocha,et al.  Changes in [3H]-glutamate uptake into platelets from patients with bipolar I disorder , 2006, Psychiatry Research.

[26]  W. Maier,et al.  Schizophrenia and bipolar disorder: differences and overlaps , 2006, Current opinion in psychiatry.

[27]  R. Burke,et al.  The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia , 2006, Molecular Psychiatry.

[28]  D. Chuang The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. , 2005, Annals of the New York Academy of Sciences.

[29]  M. Cutolo,et al.  Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line , 2005, Arthritis research & therapy.

[30]  A. Young,et al.  Hypothalamic-pituitary-adrenal axis and bipolar disorder. , 2005, The Psychiatric clinics of North America.

[31]  M. Schwald,et al.  The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. , 2004, Journal of affective disorders.

[32]  Alan J. Thomas,et al.  Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder , 2004, Biological Psychiatry.

[33]  J. Smoller,et al.  Family, twin, and adoption studies of bipolar disorder , 2003, American journal of medical genetics. Part C, Seminars in medical genetics.

[34]  F. Tanrıverdi,et al.  The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. , 2003, The Journal of endocrinology.

[35]  D. Metcalfe,et al.  Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. , 2001, Blood.

[36]  Rybakowski Jk Antiviral and immunomodulatory effect of lithium. , 2000 .

[37]  G. Illei,et al.  CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. , 1999, Journal of immunology.

[38]  G. Nabel,et al.  Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.

[39]  J. Bernhagen,et al.  Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. , 1998, Journal of immunology.

[40]  A. Zlotnik,et al.  Characterization of a novel CC chemokine, HCC-4, whose expression is increased by interleukin-10. , 1998, Blood.

[41]  F. Engelsmann,et al.  Effect of lithium maintenance treatment on hypothalamic pituitary gonadal axis in bipolar men. , 1996, Journal of psychiatry & neuroscience : JPN.

[42]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[43]  F. Belardelli Role of interferons and other cytokines in the regulation of the immune response , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[44]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[45]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[46]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[47]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[48]  J. Nurnberger,et al.  Identifying blood biomarkers for mood disorders using convergent functional genomics , 2009, Molecular Psychiatry.

[49]  S. Shamay-Tsoory,et al.  Neuropsychological evidence of impaired cognitive empathy in euthymic bipolar disorder. , 2009, The Journal of neuropsychiatry and clinical neurosciences.

[50]  R. Yolken,et al.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder , 2000, Molecular Psychiatry.

[51]  J. Rybakowski Antiviral and immunomodulatory effect of lithium. , 2000, Pharmacopsychiatry.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  K. Jamison,et al.  Life events and the course of bipolar disorder. , 1990, The American journal of psychiatry.